Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize the bulls’ thesis on OCUL.
Ocular Therapeutix Inc (OCUL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 10,777,777 | $130,842,213 | +6% | 1.29% |
| 2. | Deep Track Capital David Kroin | 8,070,414 | $97,974,826 | -33% | 1.75% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 4,625,050 | $56,148,107 | +16% | 0.08% |
| 4. | Logos Capital Arsani William | 3,500,000 | $42,490,000 | +8% | 2.57% |
| 5. | Millennium Management Israel Englander | 3,207,881 | $38,943,675 | -17% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.96 | 10,000 | $69,600.00 | 172,704 | 2025-05-08 | Filing | |
| $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | 2024-02-26 | Filing | |
| $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | 2023-12-14 | Filing | |
| $3.81 | 6,500 | $24,765.00 | 6,500 | 2023-08-30 | Filing | |
| $3.50 | 7,328 | $25,648.00 | 6,122,089 | 2022-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.04 | 11,446 | $103,471.84 | 366,356 | 2026-02-12 | Filing | |
| $9.04 | 10,348 | $93,545.92 | 332,412 | 2026-02-12 | Filing | |
| $9.04 | 124,882 | $1,128,933.28 | 3,033,078 | 2026-02-12 | Filing | |
| $9.04 | 7,863 | $71,081.52 | 318,417 | 2026-02-12 | Filing | |
| $8.54 | 6,035 | $51,538.90 | 377,802 | 2026-02-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,785,605 | $385,877,240 | 0.02% | |
| 2. | 15,602,394 | $189,413,062 | 0% | |
| 3. | 11,575,193 | $140,522,844 | 0% | |
| 4. | 11,108,555 | $134,857,858 | 97.92% | |
| 5. | 7,315,547 | $88,810,741 | 4.39% |
News See All
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential.
12 Low Priced Stocks to Buy with High Upside Potential
On December 27, Michael Farr of Farr Miller & Washington appeared on CNBC's 'Closing Bell Overtime' to talk about his market predictions for 2026.
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix Inc.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application
Ocular Therapeutix surged to a new four-year high on Monday after rallying for four consecutive days, with investor sentiment bolstered by announcements that it would officially submit a new drug application...
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences
Last week, Ocular Therapeutix Inc.
RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory
The revised target was attributed to the company’s strong execution in its SOL-1 wet age-related macular degeneration (wAMD) superiority study.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ocular Therapeutix Third Quarter 2025 Earnings Conference Call.
Hedge Fund Resource Center